Business Context and Reporting Period
Company: Rexahn Pharmaceuticals, Inc. (Note: Metadata listed "Opus Genetics," but filing text confirms Rexahn Pharmaceuticals, Inc.)
Reporting Period: Quarter ended March 31, 2011
Status: Development stage biopharmaceutical company focused on cancer, CNS disorders, and sexual dysfunction.
Capital Structure: 95,237,656 shares of common stock outstanding as of May 9, 2011.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 (Restated) |
|---|---|---|
| Revenues | $18,750 | $18,750 |
| Total Expenses | $3,932,090 | $1,611,868 |
| Net Loss | $(4,436,161) | $(8,033,596) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.11) |
| Cash and Cash Equivalents (End of Period) | $20,513,075 | $7,682,191 |
| Restricted Cash Equivalents | $3,359,456 | $401,893 |
| Warrant Liabilities | $6,114,800 | $2,966,710 |
| Accumulated Deficit | $(50,175,824) | $(45,739,663) |
Material Changes vs. Prior Period
- Revenue: Remained flat at $18,750, derived entirely from the amortization of a deferred revenue agreement with Rexgene Biotech Co., Ltd.
- Operating Expenses: Increased significantly to $3.93 million from $1.61 million.
- Research & Development (R&D): Surged 457% to $2.74 million, driven by the initiation of the Serdaxin Phase IIb clinical trial (~$1.5 million) and increased preclinical development of RX-3117.
- General & Administrative (G&A): Increased 5% to $1.11 million due to higher insurance costs and legal fees related to financial statement restatements.
- Net Loss: Decreased to $4.44 million from $8.03 million. The reduction in loss was primarily due to a decrease in the unrealized loss on the fair value of warrants ($467,625 in Q1 2011 vs. $6.56 million in Q1 2010).
- Liquidity: Cash and cash equivalents increased by $8.17 million to $20.51 million, bolstered by financing activities.
- Liabilities: Warrant liabilities increased to $6.11 million due to new issuances in March 2011.
Guidance, Outlook, and Risks
- Capital Resources: Management believes existing cash ($20.5 million) is sufficient to cover requirements through June 30, 2012. However, additional financing will be required to fully fund the operating plan.
- Development Pipeline:
- Archexin: Phase IIa trial for pancreatic cancer ongoing; estimated completion in H1 2012.
- Serdaxin: Phase IIb trial for Major Depressive Disorder (MDD) recruiting; Phase II for Parkinson's disease planned.
- Zoraxel: Phase IIb trial for erectile dysfunction expected to commence in H2 2011.
- RX-3117: Preclinical development funded by Teva Pharmaceutical Industries Limited.
- Risks:
- Going concern risk if additional financing is not secured.
- Dependence on third-party vendors for clinical trials.
- Volatility in warrant liabilities due to fair value accounting (Level 3 inputs).
- Regulatory approval uncertainties for all drug candidates.
- Unusual Items: Q1 2010 results were restated to reclassify certain warrants and anti-dilution provisions from equity to liabilities, resulting in a significant unrealized loss in the prior period.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $2.4 million quarterly operating cash burn against the $20.5 million cash balance.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the $6.1 million warrant liability and its effect on reported net loss.
- Clinical Trial Milestones: Monitor enrollment and data readouts for Serdaxin (MDD) and Zoraxel (ED) Phase IIb trials.
- Financing Needs: Confirm the timeline and terms for the anticipated additional equity or debt financing required post-June 2012.
- Restricted Cash: Note that $3.36 million of cash is restricted (primarily for Teva-funded RX-3117 development and lease letters of credit) and not available for general operations.